COPSAC COPSAC COPSAC COPSAC
  • About COPSAC
    • About
    • Organization Diagram
    • Board of Directors
    • Research team
    • Location
    • Funding
    • Logo
    • Open positions
  • COPSAC cohorts
    • COPSAC2000 cohort
    • COPSAC2010 cohort
    • COPSACSEVERE cohort
    • COPSACACUTE cohort
    • Methods
    • Data overview
      • COPSAC2000 Clinic
      • COPSAC2000 Exposures
      • COPSAC2000 Omics
      • COPSAC2000 Biobank
      • COPSAC2010 Clinic
      • COPSAC2010 Exposures
      • COPSAC2010 Omics
      • COPSAC2010 Biobank
  • Dissemination
    • Theses
    • Literature for parents
  • Research Projects
    • RestoreGut
    • COPSYCH Research Alliance
    • HEDIMED Consortium
    • EDIAQI Consortium
    • EAGLE Consortium
    • EarlyVir
  • Strategy
  • ‌

Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer.

    Home Publications Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer.
    NextPrevious

    Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer.

    By Dansk Børne Astma Center | Publications | Comments are Closed | 11 September, 1997 |

    Eur Respir J. 1997 Sep
    Nielsen KG1, Skov M, Klug B, Ifversen M, Bisgaard H.

    Abstract
    The output and size distribution of aerosols from dry powder inhalers are dependent on the flow rate through the device. Therefore, in an in vivo study, we examined the flow-dependency of the effect of formoterol when delivered from a dry powder inhaler, the Aerolizer, in a flow range relevant to schoolchildren. In a preliminary study comprising 126 asthmatic children aged 3-10 yrs, the relationship between age and peak inspiratory flow (PIF) rate through the Aerolizer was determined. Mean PIF was 104 L.min-1 and all children aged > 5 yrs performed a PIF > 60 L.min-1. Sixteen children aged 8-15 yrs with exercise-induced asthma (EIA) took part in the main trial comparing the protective effect of 12 micrograms formoterol inhaled at 60 and 120 L.min-1. The effect from high and low inspiratory flow was judged from the protective effect against EIA 12 h after drug administration. The decrease in forced expiratory volume in one second (FEV1) after exercise was 34% on the placebo day, but only 15% when formoterol was inhaled at the high flow rate. This difference was statistically significant. The decrease in FEV1 was 23% after treatment with formoterol inhaled at the low flow rate, that was not significantly different from placebo or from high-flow formoterol treatment. These clinical findings correspond with the in vitro findings of flow-dependent fine particle mass from the Aerolizer, and corroborate the relationship between fine particle mass of aerosol and clinical effect. The results indicate a flow-dependent effect of formoterol dry powder inhaled from the Aerolizer, within the range of inspiratory flow rate obtainable by school-children. This questions its applicability in children with asthma.

    PMID: 9311511

    No tags.
    NextPrevious

    CONTACT

    COPSAC
    Copenhagen Prospective Studies on Asthma in Childhood
    Copenhagen University Hospital, Herlev-Gentofte
    phone +45 3867 7360
    contact@copsac.com
    COPSAC • Copenhagen University Hospital, Herlev-Gentofte • Denmark © 2023
    • About COPSAC
      • About
      • Organization Diagram
      • Board of Directors
      • Research team
      • Location
      • Funding
      • Logo
      • Open positions
    • COPSAC cohorts
      • COPSAC2000 cohort
      • COPSAC2010 cohort
      • COPSACSEVERE cohort
      • COPSACACUTE cohort
      • Methods
      • Data overview
        • COPSAC2000 Clinic
        • COPSAC2000 Exposures
        • COPSAC2000 Omics
        • COPSAC2000 Biobank
        • COPSAC2010 Clinic
        • COPSAC2010 Exposures
        • COPSAC2010 Omics
        • COPSAC2010 Biobank
    • Dissemination
      • Theses
      • Literature for parents
    • Research Projects
      • RestoreGut
      • COPSYCH Research Alliance
      • HEDIMED Consortium
      • EDIAQI Consortium
      • EAGLE Consortium
      • EarlyVir
    • Strategy
    • ‌
    COPSAC